{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:08:27Z","timestamp":1779091707842,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.advms.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:01:58Z","timestamp":1773075718000},"page":"83-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impacts of ribociclib on the post-treatment Tp-e interval and Tp-e\/QTc ratio in breast cancer patients"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7891-0794","authenticated-orcid":false,"given":"\u015e\u00fckr\u00fc","family":"\u00c7iri\u015f","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4841-7994","authenticated-orcid":false,"given":"Mustafa","family":"Seyyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130rfan","family":"Yaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esra","family":"Polat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.advms.2026.03.002_bib1","series-title":"Breast cancer fact sheet. GLOBOCAN 2022","year":"2024"},{"key":"10.1016\/j.advms.2026.03.002_bib2","series-title":"T\u00fcrkiye fact sheet. GLOBOCAN 2022. World Health Organization","year":"2024"},{"key":"10.1016\/j.advms.2026.03.002_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.advms.2026.03.002_bib4","article-title":"Estimated number of new cases from 2022 to 2045, females, age [0-85+], Breast, World","year":"2024","journal-title":"Global Cancer Observatory: Cancer Tomorrow"},{"issue":"12","key":"10.1016\/j.advms.2026.03.002_bib5","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/annonc\/mdn424","article-title":"Prognostic factors in 1,038 women with metastatic breast cancer","volume":"19","author":"Largillier","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.advms.2026.03.002_bib6","first-page":"1","article-title":"Personalizing adjuvant endocrine therapy for early-stage hormone receptor-positive breast cancer","volume":"42","author":"Pistilli","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"19","key":"10.1016\/j.advms.2026.03.002_bib7","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"EBCTCG. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.advms.2026.03.002_bib8","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-Positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.advms.2026.03.002_bib9","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.3390\/curroncol31120548","article-title":"Timing of dose reductions and survival outcomes in metastatic breast cancer patients treated with cyclin-dependent kinase 4\/6 inhibitors","volume":"31","author":"Kubilay Tolunay","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.advms.2026.03.002_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104296","article-title":"Cardiovascular complications of ribociclib in breast cancer patients","volume":"196","author":"Fiste","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.advms.2026.03.002_bib11","author":"Bebero","year":"2019","journal-title":"The effect of addition of cyclin-dependent kinase 4 & 6 (CDK 4\/6) inhibitor to endocrine therapy in the cardiovascular toxicity in advanced breast cancer patients: A systematic"},{"key":"10.1016\/j.advms.2026.03.002_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.advms.2026.03.002_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40259-019-00382-1","article-title":"Different cardiotoxicity of Palbociclib and ribociclib in breast cancer: gene expression and pharmacological data analyses, biological basis, and therapeutic implications","volume":"33","author":"Santoni","year":"2019","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.advms.2026.03.002_bib14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.47582\/jompac.1302914","article-title":"Prospective examination of Tp-e interval and Tp-e\/QT ratio in breast cancer patients receiving radiation therapy","volume":"4","author":"Gurdal","year":"2023","journal-title":"Journal of medicine and palliative care (Online)"},{"key":"10.1016\/j.advms.2026.03.002_bib15","first-page":"353","article-title":"An analysis of the time relations of electrocardiograms","volume":"7","author":"Bazett","year":"1920","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.advms.2026.03.002_bib16","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/0002-9149(92)90562-D","article-title":"An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study)","volume":"70","author":"Sagie","year":"1992","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.advms.2026.03.002_bib17","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/abbs\/gmaa066","article-title":"Abemaciclib induces apoptosis in cardiomyocytes by activating the Hippo signaling pathway","volume":"52","author":"Zhou","year":"2020","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"10.1016\/j.advms.2026.03.002_bib18","unstructured":"Novartis Pharmaceuticals Corporation. Kisqali (Ribociclib) [Package Insert]. US Food and Drug Administration Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209092s016lbl.pdf."},{"key":"10.1016\/j.advms.2026.03.002_bib19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2147\/DDDT.S356757","article-title":"Expanding the clinical use of CDK4\/6 inhibitors in the treatment of hormone Receptor-Positive, HER2-Negative breast cancer from metastatic setting to adjuvant setting","volume":"16","author":"Abdel-Razeq","year":"2022","journal-title":"Drug Des Dev Ther"},{"issue":"6","key":"10.1016\/j.advms.2026.03.002_bib20","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.3390\/curroncol30060411","article-title":"HR+\/HER2- advanced breast cancer treatment in the first-line setting: expert review","volume":"30","author":"Jerzak","year":"2023","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.advms.2026.03.002_bib21","first-page":"27","article-title":"New insights on the toxicity on heart and vessels of breast cancer therapies","volume":"10","author":"Lanza","year":"2022","journal-title":"Med Sci"},{"key":"10.1016\/j.advms.2026.03.002_bib22","unstructured":"Ribociclib dosage guide + max dose, adjustments. Drugs com. Last updated Dec 23, 2024. Accessed 2026 Mar 1 https:\/\/www.drugs.com\/dosage\/ribociclib.html."},{"issue":"3","key":"10.1016\/j.advms.2026.03.002_bib23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jelectrocard.2011.03.004","article-title":"Assessment of repolarization heterogeneity for prediction of mortality in cardiovascular disease: peak to the end of the T wave interval and nondipolar repolarization components","volume":"44","author":"Smetana","year":"2011","journal-title":"J Electrocardiol"},{"issue":"2","key":"10.1016\/j.advms.2026.03.002_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23636","article-title":"Tp-e and (Tp-e)\/QT ratio as a non-invasive risk factors for malignant ventricular arrhythmia in patients with idiopathic ventricular premature complexes","volume":"35","author":"Zhao","year":"2021","journal-title":"J Clin Lab Anal"},{"issue":"16","key":"10.1016\/j.advms.2026.03.002_bib25","article-title":"CDK4\/6 inhibitors and cardiovascular toxicity: Real-world evidence","volume":"41","author":"Fiste","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.advms.2026.03.002_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029361","article-title":"Adverse cardiovascular events associated with cyclin-dependent kinase 4\/6 inhibitors in patients with metastatic breast cancer","volume":"12","author":"Fradley","year":"2023","journal-title":"J Am Heart Assoc"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112626000118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112626000118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:40:37Z","timestamp":1779090037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112626000118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1896112626000118"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2026.03.002","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impacts of ribociclib on the post-treatment Tp-e interval and Tp-e\/QTc ratio in breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Medical University of Bialystok. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}